Abionyx Pharma (France) Investor Sentiment

ABNX Stock  EUR 1.20  0.01  0.83%   
About 62% of Abionyx Pharma's investor base is looking to short. The analysis of current outlook of investing in Abionyx Pharma SA suggests that many traders are alarmed regarding Abionyx Pharma's prospects. The current market sentiment, together with Abionyx Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Abionyx Pharma SA stock news signals to limit their universe of possible portfolio assets.
  
over two months ago at news.google.com         
ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on Novem...
Google News at Macroaxis
over three months ago at news.google.com         
ABIONYX Pharma Announces Its 2024 Half-Year Financial Results - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
ABIONYX Pharma Monthly Statement of Total Voting Rights and Shares Forming the Companys Share Capita...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma Monthly Statement of Total Voting Rights and Shares Forming the Companys Share Capita...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription R...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined Gener...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the ...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b3 Clinica...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Monthly Statement of Total Voting Rights and Shares Forming the Companys Share Capital - Yah...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma Monthly Statement of Total Voting Rights and Shares Forming the Companys Share Capita...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024 - Yahoo...
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma Reports Full Year 2023 Earnings - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Abionyx Pharma affiche 4,1 millions deuros de trsorerie fin 2023 - Option Finance
Google News at Macroaxis
over six months ago at news.google.com         
Abionyx Rob Scott nomm directeur mdical et responsable de la RD - Option Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Abionyx Pharma that are available to investors today. That information is available publicly through Abionyx media outlets and privately through word of mouth or via Abionyx internal channels. However, regardless of the origin, that massive amount of Abionyx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Abionyx Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Abionyx Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Abionyx Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Abionyx Pharma alpha.

Abionyx Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Abionyx Stock analysis

When running Abionyx Pharma's price analysis, check to measure Abionyx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abionyx Pharma is operating at the current time. Most of Abionyx Pharma's value examination focuses on studying past and present price action to predict the probability of Abionyx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abionyx Pharma's price. Additionally, you may evaluate how the addition of Abionyx Pharma to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.